AU2018266324B2 - Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors - Google Patents

Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors Download PDF

Info

Publication number
AU2018266324B2
AU2018266324B2 AU2018266324A AU2018266324A AU2018266324B2 AU 2018266324 B2 AU2018266324 B2 AU 2018266324B2 AU 2018266324 A AU2018266324 A AU 2018266324A AU 2018266324 A AU2018266324 A AU 2018266324A AU 2018266324 B2 AU2018266324 B2 AU 2018266324B2
Authority
AU
Australia
Prior art keywords
aplnr
antagonist
antibody
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018266324A
Other languages
English (en)
Other versions
AU2018266324A1 (en
Inventor
Jingtai Cao
Eunice CHEUNG
Ivan B. Lobov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2018266324A1 publication Critical patent/AU2018266324A1/en
Application granted granted Critical
Publication of AU2018266324B2 publication Critical patent/AU2018266324B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2018266324A 2017-05-06 2018-05-04 Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors Active AU2018266324B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
US62/502,621 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (2)

Publication Number Publication Date
AU2018266324A1 AU2018266324A1 (en) 2019-11-28
AU2018266324B2 true AU2018266324B2 (en) 2024-02-01

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018266324A Active AU2018266324B2 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors

Country Status (10)

Country Link
EP (1) EP3618876A1 (enrdf_load_stackoverflow)
JP (1) JP7161494B2 (enrdf_load_stackoverflow)
KR (1) KR102667021B1 (enrdf_load_stackoverflow)
CN (1) CN110709104A (enrdf_load_stackoverflow)
AU (1) AU2018266324B2 (enrdf_load_stackoverflow)
CA (1) CA3062418A1 (enrdf_load_stackoverflow)
EA (1) EA201992630A1 (enrdf_load_stackoverflow)
IL (1) IL270267B2 (enrdf_load_stackoverflow)
MX (1) MX389729B (enrdf_load_stackoverflow)
WO (1) WO2018208625A1 (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4150766A4 (en) 2020-05-11 2023-10-25 Ascava, Inc. Exploiting locality of prime data for efficient retrieval of data that has been losslessly reduced using a prime data sieve

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150252107A1 (en) * 2013-11-20 2015-09-10 Regeneron Pharmaceuticals, Inc. APLNR Modulators and Uses Thereof
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
EP1613348B1 (en) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Methods for modulating angiogenesis with apelin compositions
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ES2861898T3 (es) 2006-06-16 2021-10-06 Regeneron Pharma Formulaciones que comprenden antagonistas de VEGF para administración intravítrea
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
MY164611A (en) 2012-01-23 2018-01-30 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
EP2836510A1 (en) 2012-04-11 2015-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
HK1220466A1 (zh) * 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. 愛帕琳融合蛋白和其用途
EP3120142B1 (en) 2014-03-20 2018-12-19 Centre National de la Recherche Scientifique (C.N.R.S.) Compounds inhibiting apelin / apj / gp130 signaling for use for treating cancer by inhibiting cancer stem cells
MA42924A (fr) * 2015-09-23 2018-08-01 Hoffmann La Roche Variants optimisés d'anticorps anti-vegf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150252107A1 (en) * 2013-11-20 2015-09-10 Regeneron Pharmaceuticals, Inc. APLNR Modulators and Uses Thereof
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eleftheriadou, M. et al., American Journal of Ophthalmology, (2016-10-14), vol. 174, pages 160 - 168, doi: 10.1016/J.AJO.2016.09.038 *
Frampton, J. 'Aflibercept for intravitreal injection: in neovascular age-related macular degeneration', Drugs Aging, (2012), vol. 29, pages. 839-846, doi: 10.1007/s40266-012-0015-2. *

Also Published As

Publication number Publication date
KR20200004366A (ko) 2020-01-13
IL270267B1 (en) 2024-02-01
IL270267A (enrdf_load_stackoverflow) 2019-12-31
KR102667021B1 (ko) 2024-05-21
JP7161494B2 (ja) 2022-10-26
CA3062418A1 (en) 2018-11-15
IL270267B2 (en) 2024-06-01
MX2019012985A (es) 2020-01-13
CN110709104A (zh) 2020-01-17
EA201992630A1 (ru) 2020-04-29
MX389729B (es) 2025-03-20
EP3618876A1 (en) 2020-03-11
AU2018266324A1 (en) 2019-11-28
JP2020518641A (ja) 2020-06-25
WO2018208625A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
US20230020514A1 (en) Methods for treating or preventing migraine headache
KR102146692B1 (ko) 항-ｐｄｇｆｒ-베타 항체 및 이의 용도
JP5896993B2 (ja) ヒトｇｄｆ８に対する抗体
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
US11104730B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
TW202108621A (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途
AU2018266324B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
WO2021259200A1 (zh) 抗ang-2抗体及其用途
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
US20220127344A1 (en) Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
US20210087282A1 (en) Anti-nrp1a antibodies and their uses for treating eye or ocular diseases
EA049293B1 (ru) АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)